First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors.

被引：0
|
作者：
Plummer, R
Middleton, M
Wilson, R
Jones, C
Evans, J
Robson, L
Steinfeldt, H
Kaufman, R
Reich, S
Calvert, AH
机构：
[1] No Ctr Canc Treatment, Newcastle Upon Tyne, Tyne & Wear, England
[2] Churchill Hosp, Oncol Unit, Oxford OX3 7LJ, England
[3] Queens Univ Belfast, Dept Oncol, Belfast, Antrim, North Ireland
[4] Beatson Oncol Ctr, Dept Med Oncol, Glasgow, Lanark, Scotland
[5] Canc Res UK, London, England
[6] Pfizer Global Res & Dev, La Jolla, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：208S / 208S
页数：1
相关论文
共 50 条
  • [21] A phase I trial of the combination of erlotinib and tipifarnib in patients with advanced solid tumors.
    Ma, CX
    Croghan, G
    Reid, J
    Hanson, L
    Mandrekar, S
    Marks, R
    Adjei, A
    Furth, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 192S - 192S
  • [22] Phase I trial of cabazitaxel plus cisplatin in patients with advanced solid tumors.
    Lockhart, Albert C.
    Sundaram, Shankar
    Sarantopoulos, John
    Mita, Monica M.
    Lane, Alex R.
    Moseley, Jennifer L.
    Dedieu, Jean-Francois
    Stash, Diane
    Zhi, Xin
    Mazuir, Florent
    Mita, Alain C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [23] Gemcitabine and Docetaxel in patients with advanced solid tumors. A GETICS phase I trial
    Jaremtchuk, AV
    Zabra, JJ
    Ferro, A
    Aman, EF
    Alvarez, R
    Arroyo, G
    Marmissolle, F
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S290 - S290
  • [24] Phase I trial of ADI-peg 20 plus docetaxel (DOC) in patients (pts) with advanced solid tumors.
    Tomlinson, Ben Kent
    Bomalaski, John S.
    Diaz, Monica
    Akande, Taiwo
    Mahaffey, Nichole
    Li, Tianhong
    Dutia, Mrinal P.
    Kelly, Karen
    Gong, I-Yeh
    Gandara, David R.
    Pan, Chong-xian
    Lara, Primo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] Phase I trial of CT-2106 (polyglutamated camptothecin) administered weekly in patients (pts) with advanced solid tumors.
    Daud, A.
    Garrett, C.
    Simon, G. R.
    Munster, P.
    Sullivan, D.
    Stromatt, S.
    Allevi, C.
    Bernareggi, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 82S - 82S
  • [26] A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors.
    Berlin, J.
    Keedy, V. L.
    Janne, P. A.
    Yee, L.
    Rizvi, N. A.
    Jin, X.
    Copigneaux, C.
    Hettmann, T.
    Beaupre, D. M.
    LoRusso, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors.
    Mehra, Ranee
    Camidge, D. Ross
    Sharma, Sunil
    Felip, Enriqueta
    Tan, Daniel Shao-Weng
    Vansteenkiste, Johan F.
    De Pas, Tommaso Martino
    Kim, Dong-Wan
    Santoro, Armando
    Liu, Geoffrey
    Goldwasser, Meredith
    Dai, David
    Radona, Marietta
    Boral, Anthony
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] A phase I trial of veliparib, an inhibitor of poly(ADP-ribose) polymerase (PARP), and topotecan (TPT) in patients with solid tumors.
    Hendrickson, Andrea Elisabeth Wahner
    Menefee, Michael E.
    Hartmann, Lynn C.
    Long, Harry J.
    Northfelt, Donald W.
    Reid, Joel M.
    Boakye-Agyeman, Fleix
    Flatten, Karen S.
    Poirier, Guy G.
    Lensing, Janet
    Erlichman, Charles
    Kaufmann, Scott H.
    Haluska, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] A HUMAN ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION STUDY OF THE PARP INHIBITOR RUCAPARIB IN PATIENTS WITH ADVANCED SOLID TUMORS.
    Liao, M.
    Watkins, S.
    Nash, E.
    Isaacson, J.
    Etter, J.
    Beltman, J.
    Shen, L.
    Mutlib, A.
    Kemeny, V.
    Papai, Z.
    Xiao, J. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S62 - S62
  • [30] A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors.
    Rudin, C. M.
    Jimeno, A.
    Miller, W. H.
    Eigl, B. J.
    Gettinger, S. N.
    Chang, A. L. S.
    Faia, K.
    Sweeney, J.
    Loewen, G.
    Ross, R. W.
    Weiss, G. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345